Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
14 Total results for product and free and sample content found
Datamonitor Healthcare
By Daniel Chancellor 01 Mar 2017
New clinical data and a deepening treatment algorithm will drive market growth
Topic Research Wire
Datamonitor Healthcare
By Dominique Fontanilla 15 Feb 2017
While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica.
Topic Research Wire
Datamonitor Healthcare
06 Jan 2017
On 5 January, Amgen secured a court ruling blocking Praluent (alirocumab; Sanofi/Regeneron) from being sold in the US. This ruling clears the way for Amgen’s Repatha (evolocumab) to potentially become the sole proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in the US market.
Topic Research Wire
Datamonitor Healthcare
12 Dec 2016
At the 2016 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Eli Lilly provided a more detailed explanation for the failure of solanezumab in its pivotal EXPEDITION 3 study in mild Alzheimer’s disease.
Datamonitor Healthcare
22 Nov 2016
Inclisiran offers patients a more convenient dosing schedule that may allow it to compete with marketed PCSK9 inhibitors when approved.
Topic Research Wire
Datamonitor Healthcare
22 Nov 2016
Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.
Topic Research Wire
Datamonitor Healthcare
22 Nov 2016
Topline results from the Phase III EFFECT-HF study of Injectafer (ferric carboxymaltose; Genesis Pharma/The Galenica Group/Zeria) and its impact on exercise capacity in chronic heart failure patients with iron deficiency were presented at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans.
Topic Research Wire
Datamonitor Healthcare
18 Nov 2016
Reduced doses of Xarelto were shown to lower the rate of bleeding in the PIONEER-AF trial. However, questions still remain as to how efficacious the smaller doses of Xarelto tested in the trial are at protecting against stroke.
Topic Research Wire
Datamonitor Healthcare
17 Nov 2016
The Phase III GLAGOV trial showed Repatha (evolocumab; Amgen/Astellas) treatment to reduce atherosclerotic plaque burden in an apparently dose-dependent manner, even at very small low-density lipoprotein-cholesterol (LDL-C) levels.
Topic Research Wire
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
